Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator Trial being conducted under FDA Special Protocol Assessment (SPA)...
Multinational Research Collaboration Advances Apabetalone Towards Phase 2 Clinical Trial for PAH Patients Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Multicenter...
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration...
VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first...
Randomized controlled study is first to demonstrate treatment efficacy using mobile devices for self-management of low back pain Kaia Health, a digital therapeutics company, announced results from the first randomized controlled trial of its app-based therapy program...
Positive Results Seen for Both Pain and Inflammation Mati Therapeutics Inc. (“Mati”) announced that it has completed a Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute®sustained ocular punctal plug drug...
Email
Text